gefitinib has been researched along with d-alpha tocopherol in 7 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (d-alpha tocopherol) | Trials (d-alpha tocopherol) | Recent Studies (post-2010) (d-alpha tocopherol) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 32,198 | 2,903 | 7,258 |
| Protein | Taxonomy | gefitinib (IC50) | d-alpha tocopherol (IC50) |
|---|---|---|---|
| Glutathione S-transferase P | Homo sapiens (human) | 0.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dvorák, J; Hyspler, R; Kalábová, H; Kasparová, M; Krcmová, L; Melichar, B; Solichová, D; Urbánek, L | 1 |
| Bachawal, SV; Sylvester, PW; Wali, VB | 2 |
| Chen, JN; Chen, SY; Lin, PS; Liu, HC; Wei, CW; Yiang, GT | 1 |
| Alanazi, FK; Alqahtani, AS; Harisa, GI; Nasr, FA; Sherif, AY | 1 |
1 review(s) available for gefitinib and d-alpha tocopherol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for gefitinib and d-alpha tocopherol
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Intestinal permeability, vitamin A absorption and serum alpha-tocopherol during therapy with gefitinib.
Topics: Adult; Aged; alpha-Tocopherol; Case-Control Studies; Female; Gefitinib; Humans; Intestinal Absorption; Intestines; Male; Middle Aged; Permeability; Quinazolines; Vitamin A | 2010 |
Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Culture Media, Serum-Free; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Mammary Neoplasms, Animal; Mice; Quinazolines; Signal Transduction; Trastuzumab; Vitamin E | 2010 |
Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Proliferation; Chromans; Erlotinib Hydrochloride; Female; Gefitinib; Mammary Neoplasms, Animal; Mice; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT Transcription Factors; Vitamin E | 2010 |
Combined treatment with vitamin E and gefitinib has synergistic effects to inhibit TGF-β1-induced renal fibroblast proliferation.
Topics: Animals; Cell Line; Cell Proliferation; Drug Synergism; Fibroblasts; Gefitinib; Gene Expression Regulation; Kidney; MAP Kinase Signaling System; Quinazolines; Rats; Transforming Growth Factor beta1; Vitamin E | 2016 |
Engineered Nanoscale Lipid-Based Formulation as Potential Enhancer of Gefitinib Lymphatic Delivery: Cytotoxicity and Apoptotic Studies Against the A549 Cell Line.
Topics: A549 Cells; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Gefitinib; Humans; Lipids; Lung Neoplasms; Nanoparticles; Particle Size; Vitamin E | 2022 |